Pre-symptomatic gene editing in preclinical models of hypertrophic cardiomyopathy shows therapeutic promise; clinical studies are now needed to assess safety and efficacy in humans.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Marian, A. J. & Braunwald, E. Circ. Res. 121, 749–770 (2017).
Maron, B. J., Maron, M. S. & Semsarian, C. J. Am. Coll. Cardiol. 60, 705–715 (2012).
Wolf, C. M. Cardiovasc. Diagn. Ther. 9, S388–S415 (2019).
Olivotto, I. et al. Lancet 396, 759–769 (2020).
Gillmore, J. D. et al. N. Engl. J. Med. 385, 493–502 (2021).
Uddin, F., Rudin, C. M. & Sen, T. Front. Oncol. 10, 1387 (2020).
Reichart, D. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02176-5 (2022).
Chai, A. C. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02190-7 (2022).
Jeong, Y. K., Song, B. & Bae, S. Mol. Ther. 28, 1938–1952 (2020).
Hakim, C. H. et al. Nat. Commun. 12, 6769 (2021).
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Strong, A. CRISPR gene-editing therapies for hypertrophic cardiomyopathy. Nat Med 29, 305–306 (2023). https://doi.org/10.1038/s41591-022-02184-5